Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vanguard Group Inc. increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 8.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,345,266 shares of the company's stock after buying an additional 333,452 shares during the period. Vanguard Group Inc. owned about 5.73% of Nurix Therapeutics worth $81,865,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of NRIX. The Manufacturers Life Insurance Company lifted its position in shares of Nurix Therapeutics by 32.4% in the third quarter. The Manufacturers Life Insurance Company now owns 30,383 shares of the company's stock valued at $683,000 after acquiring an additional 7,441 shares in the last quarter. FMR LLC raised its stake in Nurix Therapeutics by 675.9% during the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after purchasing an additional 511,256 shares during the period. Wellington Management Group LLP lifted its holdings in Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock worth $78,243,000 after purchasing an additional 280,240 shares in the last quarter. EP Wealth Advisors LLC bought a new position in Nurix Therapeutics in the 3rd quarter worth approximately $240,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Nurix Therapeutics during the 3rd quarter valued at approximately $346,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on NRIX shares. JPMorgan Chase & Co. dropped their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Wells Fargo & Company reduced their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Stifel Nicolaus cut their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Stephens reaffirmed an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, Morgan Stanley raised their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Trading Up 0.9 %

Shares of NASDAQ NRIX traded up $0.09 during midday trading on Tuesday, hitting $9.94. The company's stock had a trading volume of 86,277 shares, compared to its average volume of 895,182. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56. The firm has a market cap of $757.40 million, a P/E ratio of -3.46 and a beta of 2.23. The business's 50 day moving average is $13.84 and its two-hundred day moving average is $19.06.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period last year, the company earned ($0.76) earnings per share. On average, analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company's stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock worth $213,449 in the last 90 days. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.